Clinical Trial Update: Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States

View source ↗

Summary

A completed analysis assessing potential eligibility for Inclisiran in the United States and estimating the number of preventable cardiovascular disease events …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• LEQVIO (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cardiovascular Disease | Status: COMPLETED